Advanced Search

Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2016 April;68(2) > Minerva Urologica e Nefrologica 2016 April;68(2):227-32

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536

Frequency: Bi-Monthly

ISSN 0393-2249

Online ISSN 1827-1758

 

Minerva Urologica e Nefrologica 2016 April;68(2):227-32

NEPHROLOGY 

    ORIGINAL ARTICLES

The relationship between FGF-23 and ghrelin levels in CKD patients: preliminary data

Savas OZTURK 1, Oktay OZKAN 1, Murat EFE 2, Halil YAZICI 3, Meltem GURSU 1, Ali Hakan KAYA 3, Egemen CEBECI 1, Abdullah SUMNU 1, Serhat KARADAG 1, Sule POTUROGLU 4, Rumeyza KAZANCIOGLU 5

1 Department of Nephrology, Haseki Training and Research Hospital, Istanbul, Turkey; 2 Department of Internal Medicine, Haseki Training and Research Hospital, Istanbul, Turkey; 3 Department of Nephrology, Istanbul Medical Faculty of Istanbul University, Istanbul, Turkey; 4 Department of Gastroenterology, Haseki Training and Research Hospital, Istanbul, Turkey; 5 Department of Nephrology, Medical Faculty of Bezmialem Vakif University, Istanbul, Turkey

BACKGROUND: Fibroblast growth factor (FGF)-23 is a recently discovered phosphaturic hormone that increases in chronic kidney disease (CKD). It has been accepted as a determinant of mortality and a therapeutic target in these patients. Ghrelin is a hormone that has roles in energy and nutrient metabolism. Ghrelin level was found to be increased in CKD patients. This is a controlled study in which the relationship between FGF-23 and ghrelin levels in CKD patients has been studied.
METHODS: Three groups were involved: 88 individuals. Dialysis group (DG, 33 patients) including patients on hemodialysis (21 patients) or peritoneal dialysis program (12 patients); predialysis group (PG, 29 patients) consisting of patients with stage-3 CKD; and the control group (CG, 29 individuals) of healthy adults. Serum FGF-23 and ghrelin levels were measured as well as routine biochemical parameters.
RESULTS: FGF-23 levels were similar within the groups (CG: 268±45 pg/mL, PG: 284±94 pg/mL, DG: 259±87 pg/mL, P=0.11). Ghrelin level was higher in the PG group compared with the DG and CG, while DG had higher ghrelin level than the CG (CG: 2.79±0.38 ng/mL, PG: 4.53±1.18 ng/mL, DG: 3.98±0.89 ng/mL). When all groups were studied together; a strong correlation was found between FGF-23 and ghrelin levels. When the analysis was repeated with PG and DG accepted as CKD group; this strong correlation persisted; while it was not true for the CG.
CONCLUSIONS: There might be a strong correlation between FGF-23 and ghrelin levels irrespective of the stage of CKD and the dialysis modality. There is need for further studies to clarify the pathophysiological link between these parameters.

language: English


FULL TEXT  REPRINTS

top of page